Skip to main content

Table 2 Observed (O) and expected (E) numbers of second primary cancers after diagnosis of an initial uterine cancer (ICD-9 179, 182) in Taiwan 1979-2008

From: Increased risk of second primary malignancies following uterine cancer: a population-based study in Taiwan over a 30-year period

SPM site (ICD-9 code)

Age of uterine cancer (years) (mean ± SD)

Age of SPM (years) (mean ± SD)

O

E

SIR (O/E)

(95 % CI)

Head and neck

57.89 ± 11.95

63.67 ± 12.94

9

10.51

0.86

(0.39, 1.63)

Oral & pharynx (141, 143-5, 146,148-9)

49.50 ± 5.92

54.25 ± 8.96

4

4.81

0.83

(0.22, 2,13)

 Nasopharynx (147)

71.67 ± 8.33

77.00 ± 6.93

3

4.48

0.67

(0.13, 1.96)

 Larynx (161)

57

70

1

0.41

2.45

(0.03, 13.64)

 Major salivary glands (142)

51

55

1

0.80

1.24

(0.02, 6.92)

Digestive system

56.21 ± 10.12

63.28 ± 10.41

212

124.06

1.71

(1.49, 1.96)

 Esophagus (150)

58.00 ± 1.41

65.50 ± 7.78

2

1.57

1.28

(0.14, 4.61)

 Stomach (151)

59.92 ± 9.06

66.88 ± 8.59

25

17.09

1.46

(0.95, 2.16)

 Small intestine (152)

50.33 ± 10.45

56.50 ± 11.34

12

1.42

8.45

(4.36, 14.77)

 Colorectum (153,154)

54.70 ± 10.43

61.22 ± 10.42

119

53.05

2.24

(1.86, 2.68)

 Liver (155)

60.16 ± 6.81

69.09 ± 6.72

45

39.42

1.14

(0.83, 1.53)

 Biliary system (156)

63.67 ± 15.95

71.67 ± 13.43

3

4.82

0.62

(0.13, 1.82)

 Pancreas (157)

48.50 ± 12.57

54.17 ± 12.98

6

6.69

0.90

(0.33, 1.95)

Genital system

49.48 ± 12.52

52.57 ± 13.82

56

11.42

4.91

(3.71,6.37)

 Ovary (183)

48.40 ± 11.54

49.75 ± 11.43

40

9.65

4.15

(2.95, 5.64)

 Vagina and vulva (184)

52.19 ± 14.75

59.63 ± 16.92

16

1.77

9.06

(5.17, 14.71)

Urinary system

55.95 ± 13.10

64.14 ± 12.18

43

18.94

2.27

(1.64, 3.06)

 Urinary bladder (188)

53.89 ± 15.02

62.28 ± 14.42

18

7.79

2.31

(1.37, 3.65)

 Kidney (189)

57.44 ± 11.62

65.48 ± 10.38

25

11.16

2.24

(1.45, 3.31)

 Lung and bronchus (162)

58.63 ± 10.19

64.97 ± 10.99

72

36.81

1.96

(1.53, 2.46)

 Sarcoma (171)

48.50 ± 16.81

52.50 ± 16.45

6

6.77

0.89

(0.32, 1.93)

 Skin (173)

52.50 ± 11.57

59.14 ± 12.38

14

11.85

1.18

(0.65, 1.98)

 Breast (174)

53.41 ± 10.20

59.23 ± 10.46

95

66.51

1.43

(1.16, 1.75)

 Brain (191)

52.00 ± 9.02

54.75 ± 9.25

4

2.25

1.78

(0.48, 4.55)

 Thyroid (193)

55.46 ± 10.61

59.77 ± 11.50

13

9.84

1.32

(0.70, 2.26)

 Leukemia (204-8)

51.33 ± 7.12

58.00 ± 9.80

9

5.07

1.77

(0.81, 3.37)

 Lymphoma (200-3)

61.00 ± 7.62

67.57 ± 6.58

7

8.39

0.83

(0.33, 1.72)

 Others

50.27 ± 13.00

56.93 ± 13.80

15

12.54

1.20

(0.67, 1.97)

Total

55.01 ± 11.45

60.54 ± 12.08

555

324.95

1.71

(1.57, 1.86)

  1. Bold denotes statistical significance
  2. SD standard deviation, SIR standardized incidence ratio, SPM second primary malignancy, O observed numbers of SPMs, E expected numbers of SPMs, CI confidence interval